Cargando…

Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies

BACKGROUND: Neoadjuvant anthracycline-based chemotherapy (NAC) is a major regimen for the treatment of local advanced breast cancer (LABC), while resistance to NAC remains a paramount clinical obstacle. To investigate the role of heat shock protein 27 (Hsp27) and/or topoisomerase IIα (TopoIIα) in LA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Yixuan, Zhang, Fan, Xu, Yue, He, Lifang, Huang, Wenhe, Hong, Chaoqun, Cui, Yukun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478710/
https://www.ncbi.nlm.nih.gov/pubmed/37675221
http://dx.doi.org/10.3389/fonc.2023.1067179
_version_ 1785101409798062080
author Zhuang, Yixuan
Zhang, Fan
Xu, Yue
He, Lifang
Huang, Wenhe
Hong, Chaoqun
Cui, Yukun
author_facet Zhuang, Yixuan
Zhang, Fan
Xu, Yue
He, Lifang
Huang, Wenhe
Hong, Chaoqun
Cui, Yukun
author_sort Zhuang, Yixuan
collection PubMed
description BACKGROUND: Neoadjuvant anthracycline-based chemotherapy (NAC) is a major regimen for the treatment of local advanced breast cancer (LABC), while resistance to NAC remains a paramount clinical obstacle. To investigate the role of heat shock protein 27 (Hsp27) and/or topoisomerase IIα (TopoIIα) in LABC patients treated with NAC, we performed this retrospective study. METHODS: Associations of Hsp27 transcripts with clinic-pathological characteristics, survival and drug response were investigated in public databases. Hsp27-related genes were identified, followed by functional enrichment analyses. Besides, two protein-protein interaction networks were built. Then, tumors from 103 patients who were diagnosed with LABC and received NAC were collected, and Hsp27 and TopoIIα were examined by Immunohistochemistry (IHC). Chi-square or Fisher’s exact tests were performed, as well as survival analyses. RESULTS: Either at the transcriptional level in public databases or at the protein level tested by IHC, a high level of Hsp27 was associated with aggressive tumor characteristics such as lymph node invasion and chemotherapy resistance. Hsp27-related genes mostly involved in the metabolic pathway and the gamete generation biological process. An elevated Hsp27 indicated a poor prognosis in patients with breast cancer (log-rank test P = 0.002 and 0.004 for disease-free survival [DFS] and overall survival [OS], respectively), while it might not be an independent predictor. Of note, tumors with high TopoIIα expression (TopoIIα+) was less likely to express Hsp27 (Hsp27+), in contrast to those with TopoIIα negativity (31.1% vs. 86.2%, P<0.001), and survival analyses revealed that patients with Hsp27+ and TopoIIα- tumors had a significantly lower DFS and OS (log-rank test P < 0.001 and 0.001, respectively), in contrast to the other three groups. CONCLUSIONS: Hsp27 was associated with aggressive breast cancers and more predictable for the prognosis of LABC patients treated with NAC when concomitantly considering TopoIIα expression.
format Online
Article
Text
id pubmed-10478710
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104787102023-09-06 Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies Zhuang, Yixuan Zhang, Fan Xu, Yue He, Lifang Huang, Wenhe Hong, Chaoqun Cui, Yukun Front Oncol Oncology BACKGROUND: Neoadjuvant anthracycline-based chemotherapy (NAC) is a major regimen for the treatment of local advanced breast cancer (LABC), while resistance to NAC remains a paramount clinical obstacle. To investigate the role of heat shock protein 27 (Hsp27) and/or topoisomerase IIα (TopoIIα) in LABC patients treated with NAC, we performed this retrospective study. METHODS: Associations of Hsp27 transcripts with clinic-pathological characteristics, survival and drug response were investigated in public databases. Hsp27-related genes were identified, followed by functional enrichment analyses. Besides, two protein-protein interaction networks were built. Then, tumors from 103 patients who were diagnosed with LABC and received NAC were collected, and Hsp27 and TopoIIα were examined by Immunohistochemistry (IHC). Chi-square or Fisher’s exact tests were performed, as well as survival analyses. RESULTS: Either at the transcriptional level in public databases or at the protein level tested by IHC, a high level of Hsp27 was associated with aggressive tumor characteristics such as lymph node invasion and chemotherapy resistance. Hsp27-related genes mostly involved in the metabolic pathway and the gamete generation biological process. An elevated Hsp27 indicated a poor prognosis in patients with breast cancer (log-rank test P = 0.002 and 0.004 for disease-free survival [DFS] and overall survival [OS], respectively), while it might not be an independent predictor. Of note, tumors with high TopoIIα expression (TopoIIα+) was less likely to express Hsp27 (Hsp27+), in contrast to those with TopoIIα negativity (31.1% vs. 86.2%, P<0.001), and survival analyses revealed that patients with Hsp27+ and TopoIIα- tumors had a significantly lower DFS and OS (log-rank test P < 0.001 and 0.001, respectively), in contrast to the other three groups. CONCLUSIONS: Hsp27 was associated with aggressive breast cancers and more predictable for the prognosis of LABC patients treated with NAC when concomitantly considering TopoIIα expression. Frontiers Media S.A. 2023-08-15 /pmc/articles/PMC10478710/ /pubmed/37675221 http://dx.doi.org/10.3389/fonc.2023.1067179 Text en Copyright © 2023 Zhuang, Zhang, Xu, He, Huang, Hong and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhuang, Yixuan
Zhang, Fan
Xu, Yue
He, Lifang
Huang, Wenhe
Hong, Chaoqun
Cui, Yukun
Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
title Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
title_full Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
title_fullStr Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
title_full_unstemmed Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
title_short Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
title_sort evaluating the expression of heat shock protein 27 and topoisomerase ii α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478710/
https://www.ncbi.nlm.nih.gov/pubmed/37675221
http://dx.doi.org/10.3389/fonc.2023.1067179
work_keys_str_mv AT zhuangyixuan evaluatingtheexpressionofheatshockprotein27andtopoisomeraseiiainaretrospectivecohortofpatientsdiagnosedwithlocallyadvancedbreastcancerandtreatedwithneoadjuvantanthracyclinebasedchemotherapies
AT zhangfan evaluatingtheexpressionofheatshockprotein27andtopoisomeraseiiainaretrospectivecohortofpatientsdiagnosedwithlocallyadvancedbreastcancerandtreatedwithneoadjuvantanthracyclinebasedchemotherapies
AT xuyue evaluatingtheexpressionofheatshockprotein27andtopoisomeraseiiainaretrospectivecohortofpatientsdiagnosedwithlocallyadvancedbreastcancerandtreatedwithneoadjuvantanthracyclinebasedchemotherapies
AT helifang evaluatingtheexpressionofheatshockprotein27andtopoisomeraseiiainaretrospectivecohortofpatientsdiagnosedwithlocallyadvancedbreastcancerandtreatedwithneoadjuvantanthracyclinebasedchemotherapies
AT huangwenhe evaluatingtheexpressionofheatshockprotein27andtopoisomeraseiiainaretrospectivecohortofpatientsdiagnosedwithlocallyadvancedbreastcancerandtreatedwithneoadjuvantanthracyclinebasedchemotherapies
AT hongchaoqun evaluatingtheexpressionofheatshockprotein27andtopoisomeraseiiainaretrospectivecohortofpatientsdiagnosedwithlocallyadvancedbreastcancerandtreatedwithneoadjuvantanthracyclinebasedchemotherapies
AT cuiyukun evaluatingtheexpressionofheatshockprotein27andtopoisomeraseiiainaretrospectivecohortofpatientsdiagnosedwithlocallyadvancedbreastcancerandtreatedwithneoadjuvantanthracyclinebasedchemotherapies